J&J Medical Connect
AKEEGA®

(niraparib and abiraterone acetate)

J&J Medical Connect

Connect with us

  • Products

This information is intended for US healthcare professionals to access current scientific information about J&J Innovative Medicine products. It is prepared by Medical Information and is not intended for promotional purposes, nor to provide medical advice.

AKEEGA® (niraparib and abiraterone acetate)
Medical Information

AKEEGA - Comparison of AKEEGA with Talazoparib

Last Updated: 06/25/2026

Summary

  • No prospective, randomized, head-to-head clinical trials comparing the efficacy and safety of AKEEGA with talazoparib have been conducted.
  • Matching-adjusted indirect comparisons (MAIC) of AKEEGA with talazoparib in patients with first-line metastatic castration-resistant prostate cancer have been reported.1,2

LITERATURE SEARCH

A literature search of MEDLINE®, Embase®, BIOSIS Previews®, and Derwent Drug File (and/or other resources, including internal/external databases) was conducted on 12 June 2026.

References

Show
1 Castro E, Wang D, Walsh S, et al. Talazoparib plus enzalutamide versus olaparib plus abiraterone acetate and niraparib plus abiraterone acetate for metastatic castration-resistant prostate cancer: a matching-adjusted indirect comparison. Prostate Cancer Prostatic Dis. 2025;28(3):817-827.  
2 Castro E, Wang D, Paganelli S, et al. Matching-adjusted indirect comparisons of PARP inhibitor combinations in metastatic castration-resistant prostate cancer across key populations. Oncologist. 2026;31(5):oyag143.  

Would you like to clear and leave your conversation? Message history will be lost.